Phase 3 randomized, double-blind, controlled study of cabozantinib (XL184) versus placebo in subjects with hepatocellular carcinoma who have received prior sorafenib (CELESTIAL; NCT01908426) Meeting Abstract
| Authors: | Abou-Alfa, G. K.; Cheng, A. L.; Meyer, T.; El-Khoueiry, A. B.; Ikeda, M.; Chun, H. G.; Furuse, J.; Knox, J. J.; Okusaka, T.; Ping, J.; Borgman-Hagey, A. E.; Kelley, R. K. |
| Abstract Title: | Phase 3 randomized, double-blind, controlled study of cabozantinib (XL184) versus placebo in subjects with hepatocellular carcinoma who have received prior sorafenib (CELESTIAL; NCT01908426) |
| Meeting Title: | 2015 Gastrointestinal Cancers Symposium |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 33 |
| Issue: | 3 Suppl. |
| Meeting Dates: | 2015 Jan 15-17 |
| Meeting Location: | San Francisco, CA |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2015-01-20 |
| Language: | English |
| ACCESSION: | WOS:000356883800494 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2015.33.3_suppl.tps496 |
| Notes: | Meeting Abstract: TPS496 -- Source: Wos |
